SYRE — Spyre Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636282 ·
Last close
$106.65
Market Cap
$9.26B
52W High
$110.18
52W Low
$68.50
ADV30
935,382
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -81,639,000 | -36,200,000 | 1,173,003,000 | 162,007,000 | 71,862,000 |
| Mar 2026 | 0 | — | -75,641,000 | -69,005,000 | 763,953,000 | 97,185,000 | 93,142,000 |
| Dec 2025 | 0 | — | -57,172,000 | -62,530,000 | 777,781,000 | 85,721,000 | 62,545,000 |
| Sep 2025 | 0 | — | -56,888,000 | -11,183,000 | 504,604,000 | 64,897,000 | 49,504,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-208,944,000
Investing CF
$-463,735,000
Financing CF
$753,027,000
CapEx
—
Dividends Paid
—
Buybacks
$-117,000
EPS Diluted TTM
$-2.05
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,232,840,000
Inventory
—
Receivables
—
ST Investments
$983,339,000
EBIT TTM
$-271,340,000
Pretax Income TTM
$-178,918,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -219,562,000 | — | 777,781,000 | 62,545,000 | — | -169,252,000 |
| Dec 2024 | 0 | -208,566,000 | -208,018,000 | 608,484,000 | 90,680,000 | — | -157,410,000 |
| Dec 2023 | 886,000 | -128,564,000 | -338,790,000 | 341,859,000 | 157,843,000 | — | -99,910,000 |
| Dec 2022 | 2,329,000 | -84,781,000 | -83,815,000 | 71,144,000 | 20,839,000 | — | -80,144,000 |
| Dec 2021 | — | — | -65,801,000 | — | — | — | — |
TTM Snapshot
Revenues TTM
$174,000
NetIncome TTM
$-127,369,000
OpCashFlow TTM
$0
Assets (Latest)
$608,484,000
Forward EPS
$-3.44
Max Pain — expiry 2026-09-18
max pain strike: $105.00 · spot: $108.76 · call oi: 353 · put oi: 3,430
Expected Move to 2026-09-18:
±$23.05
(21.19%) —
implied range
$85.71 –
$131.81
· ATM straddle on $110.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.99B | $84.78 | — |
| TGTX | TG THERAPEUTICS, INC. | $8.57B | $56.01 | — |
| PTGX | Protagonist Therapeutics, Inc | $10.01B | $154.72 | — |
| ABVX | Abivax S.A. | $10.13B | $116.15 | — |
| SMMT | Summit Therapeutics Inc. | $10.16B | $12.73 | — |
News headlines (Yahoo Finance, 1h cache)
This Stock’s Already Up Nearly 600% Over the Past Year
2026-08-19 15:45 · Yahoo
Can Spyre Therapeutics (SYRE) Justify Its Premium After Positive Phase 2 Data?
2026-08-10 03:20 · Yahoo
Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know
2026-08-06 23:37 · Yahoo
A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know
2026-08-06 23:30 · Yahoo
Spyre Therapeutics Announces Grants of Inducement Awards
2026-07-02 20:05 · Yahoo
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
2026-06-29 15:16 · Yahoo
Spyre Therapeutics Shares Slide Following Large Insider Stock Sales (SYRE)
2026-06-24 12:53 · Yahoo
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential
2026-06-04 09:07 · Yahoo
Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?
2026-08-24 15:29 · Yahoo
Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?
2026-08-24 15:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.